

CITATION REPORT

List of articles citing

Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice

DOI: 10.1016/s0002-9440(10)62228-6

American Journal of Pathology, 2005, 166, 15-25.

Source: <https://exaly.com/paper-pdf/39375838/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
145	Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice. 2005 , 99, 2398-405		43
144	Platelet-derived growth factor D induces cardiac fibrosis and proliferation of vascular smooth muscle cells in heart-specific transgenic mice. 2005 , 97, 1036-45		106
143	Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. 2005 , 112, 1136-44		223
142	Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload. 2006 , 69, 657-65		82
141	Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model. 2006 , 12, 314-25		22
140	Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. 2006 , 48, 979-87		74
139	Current World Literature. 2006 , 15, 78-95		
138	Statins modulate expression of components of the plasminogen activator/plasmin system in human cardiac myocytes in vitro. 2006 , 4, 476-9		9
137	Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling. 2006 , 69, 574-84		56
136	What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?. 2006 , 69, 585-94		45
135	Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. 2006 , 69, 726-35		66
134	Myocardial proteases and matrix remodeling in inflammatory heart disease. 2006 , 69, 646-56		84
133	beta-Adrenergic receptor-stimulated apoptosis in adult cardiac myocytes involves MMP-2-mediated disruption of beta1 integrin signaling and mitochondrial pathway. 2006 , 290, C254-61		59
132	Matrix reloaded: the matrix metalloproteinase paradox. 2006 , 47, 640-1		14
131	Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. 2006 , 47, 711-7		130
130	Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. 2006 , 281, 15345-51		34
129	Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. 2006 , 114, 565-73		87

128	Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. 2007 , 115, 475-82		105
127	Matrix metalloproteinases as valid clinical targets. 2007 , 13, 333-46		220
126	Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. 2007 , 87, 1285-342		861
125	Acute and chronic effects of cardiac resynchronization in patients developing heart failure with long-term pacemaker therapy for acquired complete atrioventricular block. 2007 , 9, 869-74		32
124	Spatial disruption and enhanced degradation of collagen with the transition from compensated ventricular hypertrophy to symptomatic congestive heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 292, H1364-72	5.2	34
123	The development of cardiac fibrosis in low tissue factor mice is gender-dependent and is associated with differential regulation of urokinase plasminogen activator. 2007 , 42, 559-71		15
122	Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. 2007 , 133, 1144-55		48
121	Endogenous urokinase lacks antifibrotic activity during progressive renal injury. 2007 , 293, F12-9		33
120	Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. 2007 , 6, 480-98		577
119	Cellular and molecular mechanisms of fibrosis. 2008 , 214, 199-210		2808
118	Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. 2008 , 194, 3-21		77
117	Cardiac tissue factor: roles in physiology and fibrosis. 2008 , 35, 342-8		6
116	Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. 2008 , 156, 85-91		71
115	EMMPRIN mediates beta-adrenergic receptor-stimulated matrix metalloproteinase activity in cardiac myocytes. 2008 , 44, 210-7		42
114	Gene expression profiling of human mesenchymal stem cells for identification of novel markers in early- and late-stage cell culture. 2008 , 144, 399-408		44
113	Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. 2008 , 1, 249-57		40
112	Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. 2008 , 117, 1574-82		67
111	Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. 2008 , 77, 371-9		57

110	Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 295, H352-60	5.2	29
109	Response to Letter Regarding Article, Ablation of Matrix Metalloproteinase-9 Increases Severity of Viral Myocarditis in Mice 2008 , 118,		
108	Matrix Metalloproteinases in Tissue Remodelling and Inflammation. 2008 ,		5
107	Matrix metalloproteinases in hypertensive heart disease: new mechanistic insights. 2008 , 31, 1061-2		1
106	Transgenic expression of matrix metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model. 2008 , 31, 725-35		43
105	Myocardial infarction following atherosclerosis in murine models. 2008 , 9, 217-23		7
104	Urokinase and its receptors in chronic kidney disease. 2008 , 13, 5462-78		28
103	Matrix metalloproteinase (MMP)-9, but not MMP-2, is involved in the development and progression of C protein-induced myocarditis and subsequent dilated cardiomyopathy. 2009 , 183, 4773-81		39
102	Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. 2009 , 284, 4439-50		91
101	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. 2009 , 11, 119-29		248
100	Food-restriction in obese dyslipidaemic diabetic mice partially restores basal contractility but not contractile reserve. 2009 , 11, 1118-25		9
99	Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. 2009 , 120, 1585-97		81
98	Matrix metalloproteinases in the pathogenesis of viral heart disease. 2009 , 19, 21-6		19
97	Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells. 2009 , 325, 15-23		40
96	ZAK induces MMP-2 activity via JNK/p38 signals and reduces MMP-9 activity by increasing TIMP-1/2 expression in H9c2 cardiomyoblast cells. 2009 , 325, 69-77		19
95	Emerging concepts in cardiac matrix biology. 2009 , 87, 996-1008		52
94	Fibrosis in the GI Tract: Pathophysiology, Diagnosis and Treatment Options. 2009 , 15-31		5
93	FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. 2010 , 105, 301-13		84

92	Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension. 2010 , 18, 58-64		34
91	Persistent plasminogen activator inhibitor 1 gene expression in cardiac transplant recipients with idiopathic dilated cardiomyopathy. 2010 , 139, 1644-51		
90	Salvianolic acid B functioned as a competitive inhibitor of matrix metalloproteinase-9 and efficiently prevented cardiac remodeling. 2010 , 10, 10		41
89	Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity. 2010 , 18, 2241-6		38
88	Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. 2010 , 151, 322-31		65
87	Role of the urokinase plasminogen activator receptor in mediating impaired efferocytosis of anti-SSA/Ro-bound apoptotic cardiocytes: Implications in the pathogenesis of congenital heart block. 2010 , 107, 374-87		21
86	Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 299, H1242-54	5.2	63
85	Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition. 2010 , 122, 1200-9		100
84	Effect of fumagillin on adipocyte differentiation and adipogenesis. 2010 , 1800, 425-9		9
83	Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. 2010 , 411, 1940-4		29
82	Ventricular remodeling and function: insights using murine echocardiography. 2010 , 48, 512-7		28
81	TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'. 2010 , 48, 445-53		96
80	Matrix Metalloproteinases and their Inhibitors in Hypertensive Cardiac Remodelling. 2010 , 17, 201-208		
79	The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy. 2011 , 13, 602-10		50
78	Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. <i>American Journal of Pathology</i> , 2011 , 179, 1733-45	5.8	134
77	Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. 2011 , 92, 57-65		61
76	Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase activity in pressure overload-induced cardiac failure. 2011 , 123, 391-9		52
75	Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. 2011 , 124, 2082-93		67

74	Decreased metalloprotease 9 induction, cardiac fibrosis, and higher autophagy after pressure overload in mice lacking the transcriptional regulator p8. 2011 , 301, C1046-56	25
73	Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. 2012 , 30, 3-16	73
72	Mitochondrial mitophagic mechanisms of myocardial matrix metabolism and remodelling. 2012 , 118, 31-42	21
71	Age-related divergent remodeling of the cardiac extracellular matrix in heart failure: collagen accumulation in the young and loss in the aged. 2012 , 53, 82-90	71
70	Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes. 2012 , 33, 119-208	157
69	Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. 2012 , 5, 15	492
68	Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated α -integrin-dependent cell migration. 2012 , 443, 491-503	22
67	Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats. 2012 , 112, 2943-55	32
66	PAI-1 in tissue fibrosis. 2012 , 227, 493-507	383
65	Improvement of left ventricular remodeling after myocardial infarction with eight weeks L-thyroxine treatment in rats. 2013 , 11, 40	44
64	The oxygen free radicals control MMP-9 and transcription factors expression in the spontaneously hypertensive rat. 2013 , 90, 154-61	12
63	Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. 2013 , 48, 222-72	465
62	Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. 2013 , 304, L709-21	117
61	Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. 2013 , 28, 391-403	248
60	Urokinase plasminogen activator induces pro-fibrotic/m2 phenotype in murine cardiac macrophages. <i>PLoS ONE</i> , 2013 , 8, e57837	3-7 25
59	Matrix metalloproteinases and their inhibitors in cardiovascular pathologies: current knowledge and clinical potential. 2014 , 21	7
58	Transcriptional changes in bone marrow stromal cells of patients with heart failure. 2014 , 13, 1495-500	3
57	Nitric oxide-matrix metalloproteinase-9 interactions: biological and pharmacological significance--NO and MMP-9 interactions. 2014 , 1843, 603-17	65

56	Tissue inhibitor of metalloproteinase-1 and -3 improves cardiac function in an ischemic cardiomyopathy model rat. 2014 , 20, 3073-84		26
55	Matrix metalloproteinases and left ventricular function and structure in spinal cord injured subjects. 2014 , 437, 136-40		6
54	The importance of matrix metalloproteinase-3 in respiratory disorders. 2014 , 8, 411-21		13
53	Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. 2014 , 19, 681-94		104
52	Matrix metalloproteinases and protein tyrosine kinases: potential novel targets in acute lung injury and ARDS. 2014 , 146, 1081-1091		50
51	Lumbrokinase from earthworm extract ameliorates second-hand smoke-induced cardiac fibrosis. <i>Environmental Toxicology</i> , 2015 , 30, 1216-25	4.2	14
50	Angiotensinase C mRNA and Protein Downregulations Are Involved in Ethanol-Deteriorated Left Ventricular Systolic Dysfunction in Spontaneously Hypertensive Rats. 2015 , 2015, 409350		
49	Hypertension in African Americans with heart failure: progression from hypertrophy to dilatation; perhaps not. 2015 , 22, 61-8		1
48	Cardiac Fibrosis and Heart Failure: Cause or Effect?. 2015 ,		3
47	Overexpression of SerpinE2/protease nexin-1 Contribute to Pathological Cardiac Fibrosis via increasing Collagen Deposition. 2016 , 6, 37635		19
46	Human paraoxonase gene cluster overexpression alleviates angiotensin II-induced cardiac hypertrophy in mice. 2016 , 59, 1115-1122		11
45	Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats. <i>Cellular Physiology and Biochemistry</i> , 2016 , 39, 47-60	3.9	8
44	Emerging pharmacologic targets and treatments for myocarditis. <i>Pharmacology & Therapeutics</i> , 2016 , 161, 40-51	13.9	32
43	Attenuation of the LPS-induced, ERK-mediated upregulation of fibrosis-related factors FGF-2, uPA, MMP-2, and MMP-9 by <i>Carthamus tinctorius</i> L in cardiomyoblasts. <i>Environmental Toxicology</i> , 2017 , 32, 754-763	4.2	21
42	A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease. <i>Frontiers in Pharmacology</i> , 2017 , 8, 186	5.6	63
41	Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2018 , 55, 254-270	12.3	1
40	Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly. <i>Pharmacology & Therapeutics</i> , 2019 , 193, 99-120	13.9	20
39	ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts. <i>Chemico-Biological Interactions</i> , 2019 , 306, 62-69	5	14

38	Overexpression of IGF-IIR regulates cardiac remodeling and aggravates high salt induced apoptosis and fibrosis in transgenic rats. <i>Environmental Toxicology</i> , 2019 , 34, 210-218	4.2	6
37	A comparative analysis of the molecular basis of fibrosis between tissues. <i>Comparative Clinical Pathology</i> , 2019 , 28, 865-878	0.9	
36	Bioactive peptides attenuate cardiac hypertrophy and fibrosis in spontaneously hypertensive rat hearts. <i>Journal of Food and Drug Analysis</i> , 2020 , 28, 94-102	7	6
35	MMP9 inhibition increases autophagic flux in chronic heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020 , 319, H1414-H1437	5.2	9
34	In-depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 10042-10051	5.6	4
33	Antihypertensive and Antifibrosis Effects of Acupuncture at PC6 Acupoints in Spontaneously Hypertensive Rats and the Underlying Mechanisms. <i>Frontiers in Physiology</i> , 2020 , 11, 734	4.6	2
32	Matrix Metalloproteinases and Hypertension-Mediated Organ Damage: Current Insights. <i>Integrated Blood Pressure Control</i> , 2020 , 13, 157-169	3.5	3
31	Early Moderate Intensity Aerobic Exercise Intervention Prevents Doxorubicin-Caused Cardiac Dysfunction Through Inhibition of Cardiac Fibrosis and Inflammation. <i>Cancers</i> , 2020 , 12,	6.6	14
30	Extracellular heat shock protein HSC70 protects against lipopolysaccharide-induced hypertrophic responses in rat cardiomyocytes. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 128, 110370	7.5	5
29	Macrophage-derived MMP-9 enhances the progression of atherosclerotic lesions and vascular calcification in transgenic rabbits. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 4261-4274	5.6	16
28	Tenascin-C aggravates ventricular dilatation and angiotensin-converting enzyme activity after myocardial infarction in mice. <i>ESC Heart Failure</i> , 2020 , 7, 2113-2122	3.7	12
27	Network model-based screen for FDA-approved drugs affecting cardiac fibrosis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 377-388	4.5	1
26	Fibrosis after Myocardial Infarction: An Overview on Cellular Processes, Molecular Pathways, Clinical Evaluation and Prognostic Value. <i>Medical Sciences (Basel, Switzerland)</i> , 2021 , 9,	3.3	3
25	A Porcine Model of Heart Failure With Preserved Ejection Fraction Induced by Chronic Pressure Overload Characterized by Cardiac Fibrosis and Remodeling. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 677727	5.4	4
24	Innate Immune Cells in Pressure Overload-Induced Cardiac Hypertrophy and Remodeling. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 659666	5.7	3
23	Reversion inducing cysteine rich protein with Kazal motifs and cardiovascular diseases: The RECKlessness of adverse remodeling. <i>Cellular Signalling</i> , 2021 , 83, 109993	4.9	2
22	Traditional Chinese medicine as a therapeutic option for cardiac fibrosis: Pharmacology and mechanisms. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 142, 111979	7.5	2
21	Inflammation and cardiac remodeling during viral myocarditis. <i>Ernst Schering Research Foundation Workshop</i> , 2006 , 197-218		16

20	ECM remodeling in hypertensive heart disease. <i>Journal of Clinical Investigation</i> , 2007 , 117, 568-75	15.9	642
19	Correlation between growth differentiation factor-15 and collagen metabolism indicators in patients with myocardial infarction and heart failure. <i>Journal of Geriatric Cardiology</i> , 2016 , 13, 88-93	1.7	4
18	Global gene expression profiling in PAI-1 knockout murine heart and kidney: molecular basis of cardiac-selective fibrosis. <i>PLoS ONE</i> , 2013 , 8, e63825	3.7	27
17	Myocardial Proteases and Matrix Remodeling in Acute Myocarditis and Inflammatory Cardiomyopathy. 2010 , 71-88		
16	MMPs in Cardiovascular Diseases: Emerging Pharmacological Targets. 2014 , 407-426		1
15	Overview of Oxidative Stress and Cardiovascular Disease. 2014 , 719-764		
14	Mechanisms of Cardiac Fibrosis and Heart Failure. 2015 , 279-297		
13	Association of Matrix Metalloproteinases with CVD: Functional Aspects. 2017 , 473-496		
12	G Protein-Coupled Estrogen Receptor 30 Reduces Transverse Aortic Constriction-Induced Myocardial Fibrosis in Aged Female Mice by Inhibiting the ERK1/2 -MMP-9 Signaling Pathway. <i>Frontiers in Pharmacology</i> , 2021 , 12, 731609	5.6	0
11	MMP roles in the initiation and progression of cardiac remodeling leading to congestive heart failure. 2008 , 99-122		1
10	Influence of the plasminogen activator system on necrosis in acute myocardial infarction: analysis of urokinase- and urokinase receptor-knockout mouse models. <i>American Journal of Translational Research (discontinued)</i> , 2019 , 11, 3629-3636	3	1
9	Early IL-17A production helps establish Mycobacterium intracellulare infection in mice.. <i>PLoS Pathogens</i> , 2022 , 18, e1010454	7.6	0
8	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. <i>Nature Communications</i> , 2021 , 12, 7112	17.4	2
7	Exercise intervention prevents early aged hypertension-caused cardiac dysfunction through inhibition of cardiac fibrosis. <i>Aging</i> ,	5.6	0
6	Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology. <i>Pharmacological Reviews</i> , 2022 , 74, 712-768	22.5	5
5	Dipeptide IF and Exercise Training Attenuate Hypertension in SHR Rats by Inhibiting Fibrosis and Hypertrophy and Activating AMPK α , SIRT1, and PGC1 α 2022 , 23, 8167		0
4	Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy.		1
3	Fibrotic remodeling and tissue regeneration mechanisms define the therapeutic potential of human muscular progenitors.		0

- 2 Distinguishing Plasmin-Generating Microvesicles: Tiny Messengers Involved in Fibrinolysis and Proteolysis. **2023**, 24, 1571 ○
- 1 Targeting interleukin-21 inhibits stress overload-induced cardiac remodelling via the TIMP4/MMP9 signalling pathway. **2023**, 940, 175482 ○